DiaMedica reiterates plan for ReMEDy2 interim analysis in 2H 2026 as stroke trial approaches 70% of 200 patients
WhatDiaMedica has reaffirmed its plan to conduct an interim analysis of the ReMEDy2 trial in the second half of 2026, marking a significant milestone in the ongoing clinical study for its stroke treatment.
WhyThe company's decision to stick to its original timeline is likely driven by the trial's steady progress, with over 70% of the targeted 200 patients already enrolled.
SignalThe ReMEDy2 trial aims to evaluate the efficacy and safety of DiaMedica's treatment in reducing the risk of recurrent ischemic strokes, and the interim analysis will provide crucial insights into the therapy's potential benefits and risks.
TargetThe trial's primary endpoint is to demonstrate a significant reduction in the rate of recurrent ischemic strokes in patients treated with DiaMedica's therapy compared to a placebo, which would be a major breakthrough in the treatment of this debilitating condition.
RiskWhile the trial's progress is encouraging, there are still risks associated with the interim analysis, including the potential for unexpected safety issues or efficacy concerns that could impact the trial's outcome and the future of DiaMedica's treatment.